Sugi Predict

Sugi Predict / Compounds / SCHEMBL6729

SCHEMBL6729

SCHEMBL6729

O=C(O)Nc1ncc(Br)s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 1/20 0.59
▸ CDK2 P24941 1/20 0.59
▸ CDK5 Q00535 1/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ MAPK10 P53779 1/20 0.57
▸ FBP1 P09467 11/20 0.52
▸ NPC1 O15118 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749806 0.82 SMN1; SMN2 (0.59) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL14476229 0.82 SMN1; SMN2 (0.55) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL27783851 0.81 CCNE1 (0.49) CCNE1CDK2CDK5SMN1; SMN2MAPK10
Ammonia Solution, Strong SCHEMBL27883952 0.81 SMN1; SMN2 (0.58) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL4479801 0.79 SMN1; SMN2 (0.56) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL5836346 0.79 SMN1; SMN2 (0.65) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL836669 0.79 KDR (0.68) CCNE1CDK2CDK5SMN1; SMN2FBP1
SCHEMBL2650712 0.78 SMN1; SMN2 (0.54) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL17353987 0.78 SMN1; SMN2 (0.72) CCNE1CDK2CDK5SMN1; SMN2MAPK10
SCHEMBL6278411 0.78 SMN1; SMN2 (0.55) CCNE1CDK2CDK5SMN1; SMN2MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4469035-A1 IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE Bridgene Biosciences, Inc. (US) 2024-12-04 — — EP disclosed
US-20240208960-A1 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS TAKEDA PHARMACEUTICALS U.S.A., INC. 2024-06-27 — — US disclosed
US-11999721-B2 Pyrazole compounds and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-06-04 — — US disclosed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
WO-2024006956-A9 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-04-11 — — WO disclosed
WO-2024069592-A1 N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE REPARE THERAPEUTICS INC. (CA) 2024-04-04 — — WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 — — WO disclosed
WO-2024006956-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 — — WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
US-11753404-B2 Aminothiazole compounds as c-Kit inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
WO-2008061236-A2 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2008-05-22 — — WO disclosed
US-20080108608-A1 Pyrimidines With Tie2 (Tek) Activity ASTRAZENECA AB (SE) 2008-05-08 — — US disclosed
EP-1863805-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-12-12 — — EP disclosed
WO-2007133562-A2 MONOCYCLIC HETEROARYL COMPOUNDS ARIAD PHARMACEUTICALS, INC. (US) 2007-11-22 — — WO disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 — — WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 — — US disclosed
CN-1917879-A Pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2007-02-21 — — CN disclosed
EP-1737463-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY AstraZeneca AB (SE) 2007-01-03 — — EP disclosed
WO-2006082373-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 — — WO disclosed
WO-2005060970-A1 PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2005-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753404-B2 Aminothiazole compounds as c-Kit inhibitors KIT, TNNI3K, CKS1B CCNE1 17/4885CDK2 11/4885CDK5 188/4885
US-11999721-B2 Pyrazole compounds and uses thereof CYP11B2, CYP11B1, TPMT CCNE1 3365/4885CDK2 700/4885CDK5 790/4885
US-20080108608-A1 Pyrimidines With Tie2 (Tek) Activity TIE1, TEK, TEKT1 CCNE1 361/4885CDK2 62/4885CDK5 988/4885
US-20240208960-A1 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS KIT, TNNI3K, CKS1B CCNE1 17/4885CDK2 11/4885CDK5 188/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 CCNE1 1003/4885CDK2 2917/4885CDK5 1058/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 CCNE1 1803/4885CDK2 62/4885CDK5 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.